Neurodegenerative diseases are often
caused by uncontrolled amyloid
aggregation. Hence, many drug discovery processes are oriented to
evaluate new compounds that are able to modulate self-recognition
mechanisms. Herein, two related glycoconjugate pentacoordinate Pt(II)
complexes were analyzed in their capacity to affect the self-aggregation
processes of two amyloidogenic fragments, Aβ21–40 and Aβ25–35, of the C-terminal region of
the β-amyloid (Aβ) peptide, the major component of Alzheimerʼs
disease (AD) neuronal plaques. The most water-soluble complex, 1Pt
dep
, is able to bind both fragments
and to deeply influence the morphology of peptide aggregates. Thioflavin
T (ThT) binding assays, electrospray ionization mass spectrometry
(ESI-MS), and ultraviolet–visible (UV–vis) absorption
spectroscopy indicated that 1Pt
dep
shows different kinetics and mechanisms of inhibition toward the
two sequences and demonstrated that the peptide aggregation inhibition
is associated with a direct coordinative bond of the compound metal
center to the peptides. These data support the in vitro ability of pentacoordinate Pt(II) complexes to inhibit the formation
of amyloid aggregates and pave the way for the application of this
class of compounds as potential neurotherapeutics.